There are 2789 resources available
625P - TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
Presenter: Caterina Aversa
Session: ePoster Display
626P - Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study
Presenter: Nobuaki Matsubara
Session: ePoster Display
583P - Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
Presenter: Vincenza Conteduca
Session: ePoster Display
584P - Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Stephane Oudard
Session: ePoster Display
585P - Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Cora Sternberg
Session: ePoster Display
586P - Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: ePoster Display
710P - Comprehensive genomic profiling (CGP) of small cell neuroendocrine carcinoma of the bladder (NEBC)
Presenter: Andrea Necchi
Session: ePoster Display
711P - Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
Presenter: Cedric Pobel
Session: ePoster Display
712P - Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor
Presenter: Roman Sosnowski
Session: ePoster Display